Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CD74 | P04233 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737819 | 0.86 | CCR1 (0.57) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL13739148 | 0.83 | CCR1 (0.53) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL1716529 | 0.77 | CCR1 (0.63) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL6176904 | 0.77 | CCR1 (0.63) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL28491343 | 0.75 | CCR1 (0.55) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL1088335 | 0.74 | CCR1 (1.00) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL30019238 | 0.74 | METAP2 (0.55) | CCR1ALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL3462719 | 0.74 | AURKA (0.41) | ALDH1A1LMNAPARP1SLC40A1KDM4E | |
| SCHEMBL11802591 | 0.74 | CCR1 (0.59) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 | |
| SCHEMBL1721909 | 0.73 | FGFR4 (0.46) | CCR1FGFR4MAPKAPK2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981912-B | Phosphoric acid triester DOPO derivative flame retardant and preparation method thereof | 寿光卫东化工有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-110981912-A | Phosphoric acid triester DOPO derivative flame retardant and preparation method thereof | 寿光卫东化工有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-103492377-B | As the triazolopyridine compounds of PIM kinase inhibitor | ARRAY BIOPHARMA INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| CN-103492377-A | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC | 2014-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | CCR1 3163/4885FGFR4 850/4885MAPKAPK2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.